CTi Biopharma Corp Analysis
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
CTi Biopharma Corp is overvalued with Real Value of 6.66 and Hype Value of 9.09. The main objective of CTi Biopharma delisted stock analysis is to determine its intrinsic value, which is an estimate of what CTi Biopharma Corp is worth, separate from its market price. There are two main types of CTi Biopharma's stock analysis: fundamental analysis and technical analysis.
The CTi Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and CTi Biopharma's ongoing operational relationships across important fundamental and technical indicators.
CTi |
CTi Stock Analysis Notes
About 83.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.54. CTi Biopharma Corp last dividend was issued on the 3rd of January 2017. The entity had 1:10 split on the 3rd of January 2017. CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people. For more info on CTi Biopharma Corp please contact MBA MD at 206 282 7100 or go to https://www.ctibiopharma.com.CTi Biopharma Corp Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. CTi Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding CTi Biopharma Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| CTi Biopharma Corp is not yet fully synchronised with the market data | |
| CTi Biopharma Corp has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 53.95 M. Net Loss for the year was (92.99 M) with profit before overhead, payroll, taxes, and interest of 50.43 M. | |
| CTi Biopharma Corp currently holds about 81.64 M in cash with (81.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies |
CTi Biopharma Corp Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CTi Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of August 2023 Upcoming Quarterly Report | View | |
| 6th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
CTi Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.2 B.CTi Profitablity
The company has Profit Margin (PM) of (0.91) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.74) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.74.CTi Biopharma Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CTi Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on CTi Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CTi Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Reed Tuckson over a year ago Acquisition by Reed Tuckson of 80000 shares of CTi Biopharma subject to Rule 16b-3 | ||
Reed Tuckson over a year ago Bona fide gift to Reed Tuckson of 43785 shares of CTi Biopharma subject to Section 16 |
CTi Biopharma Outstanding Bonds
CTi Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CTi Biopharma Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CTi bonds can be classified according to their maturity, which is the date when CTi Biopharma Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| CSX P 6 Corp BondUS126408GH06 | View | |
| CSX P 615 Corp BondUS126408GK35 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| CSX P 622 Corp BondUS126408GS60 | View | |
| CSNABZ 4625 10 JUN 31 Corp BondUS12644VAD01 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| CSX P 475 Corp BondUS126408GW72 | View |
CTi Biopharma Predictive Daily Indicators
CTi Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CTi Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About CTi Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how CTi Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CTi shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as CTi Biopharma. By using and applying CTi Stock analysis, traders can create a robust methodology for identifying CTi entry and exit points for their positions.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding CTi Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets |